# Chava Kimchi-Sarfaty Back to [[Ribosome Pausing and Cotranslational Folding]] · [[Research and Evidence]] **Role:** FDA (CBER) researcher on synonymous mutations and therapeutic proteins ⚠️ - Lead author of [Kimchi-Sarfaty et al. 2007](https://doi.org/10.1126/science.1135308): a "silent" MDR1 polymorphism changes P-glycoprotein substrate specificity. - Co-author of the review [Sauna & Kimchi-Sarfaty 2011](https://doi.org/10.1038/nrg3051) on synonymous mutations. - Last author of [Alexaki et al. 2019](https://doi.org/10.1038/s41598-019-51984-2): a codon-optimized factor IX differed in conformation, with changed translation kinetics. Directly relevant to the post's "optimizing away the instructions" line. ⚠️ Affiliations are from general knowledge and were not rechecked for this note; the papers linked were verified via CrossRef or the publisher.